The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Med.
Sec. Family Medicine and Primary Care
Volume 11 - 2024 |
doi: 10.3389/fmed.2024.1400049
This article is part of the Research Topic Advances in the Management of Lung Cancer: From the Bench to the Bedside and Back View all 4 articles
Risk score model for predicting mortality among patients with lung cancer
Provisionally accepted- 1 Uijeongbu Eulji Medical Center, Eulji University, Gyeonggi, Republic of Korea
- 2 University of Seoul, Seoul, Republic of Korea
- 3 College of Medicine, University of Ulsan, Ulsan, Republic of Korea
- 4 Asan Medical Center, College of Medicine, University of Ulsan, SONGPA-GU, Seoul, Republic of Korea
Background: To develop an accurate mortality risk predictive model among patients with lung cancer. Methods: The development cohort included 96,255 patients with lung cancer aged ≥19 years, who underwent a Korean National Health Insurance Service health check-up from 2005 to 2015. The validation cohort consisted of 18,432 patients (≥19 years) with lung cancer from another region. The outcome was all-cause mortality between January 1, 2005, and December 31, 2020.Results: Approximately 60.5% of the development cohort died within a median follow-up period of 2.32 (0.72-5.00) years. Risk score was highest in participants aged ≥65 years, followed by those who underwent treatment, had a history of emergency room visits, and were current smokers. Participants treated by surgery had the lowest risk score, followed by combined surgery and chemotherapy, combined surgery and radiation therapy, women, and regular exercisers. The C statistic in the development and validation cohorts was 0.78 (95% confidence interval: 0.77-0.78) and 0.81 (95% confidence interval: 0.78-0.84), respectively.Conclusions: Advanced age, lung cancer stage, and treatment type were strong risk factors of mortality in lung cancer patients, while women sex and exercise were preventive factors. These will aid in the prediction of mortality and management of lung cancer patients.
Keywords: lung cancer, Mortality, risk score, development cohort, Validation cohort
Received: 12 Mar 2024; Accepted: 27 Aug 2024.
Copyright: © 2024 HUH, KIM, Kim and Son. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ki Young Son, Asan Medical Center, College of Medicine, University of Ulsan, SONGPA-GU, 05505, Seoul, Republic of Korea
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.